Curated News
By: NewsRamp Editorial Staff
May 30, 2024
PaxMedica Prepares NDA Submission for Suramin to Treat Human African Trypanosomiasis
Discuss on Reddit
Discuss on SubstackTLDR
- PaxMedica is advancing suramin treatment for Human African Trypanosomiasis, creating a potential advantage in the neurological disorder treatment market.
- PaxMedica is preparing to submit a New Drug Application to the FDA and is planning a Type C meeting to address specific drug development issues.
- PaxMedica's progress toward establishing suramin as a HAT treatment could make the world a better place by providing a well-established treatment for a devastating disease.
- PaxMedica's commitment to advancing suramin treatment for HAT demonstrates dedication to improving global health and addressing neurological disorders.
Impact - Why it Matters
This news matters as it represents progress towards finding a treatment for a debilitating disease that affects many people in East Africa. If successful, this treatment could greatly impact the lives of those affected by Human African Trypanosomiasis.
Summary
PaxMedica, a biopharmaceutical company, is preparing to submit a New Drug Application to the U.S. Food and Drug Administration for using suramin to treat Human African Trypanosomiasis, also known as sleeping sickness. This comes as a significant step in establishing suramin as an accepted treatment for the disease, with PaxMedica currently preparing for an important Type C meeting with the FDA in June.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, PaxMedica Prepares NDA Submission for Suramin to Treat Human African Trypanosomiasis
